BHCM
CRBU icon

Brevan Howard Capital Management’s Caribou Biosciences CRBU Stock Holding History

Brevan Howard Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-65,062
Closed -$124K – 2157
2026
Q1 		$124K Buy
+65,062
New +$112K ﹤0.01% 1991
2025
Q3 		– Sell
-155,521
Closed -$196K – 1989
2025
Q2 		$196K Buy
+155,521
New +$153K ﹤0.01% 1714
2024
Q3 		– Sell
-77,121
Closed -$126K – 1185
2024
Q2 		$126K Buy
77,121
+66,867
+652% +$214K ﹤0.01% 949
2024
Q1 		$52.7K Buy
+10,254
New +$63.2K ﹤0.01% 935

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Brevan Howard Capital Management's CRBU Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Caribou Biosciences (CRBU) in Q2 2026, closing a stake of 65,062 shares — an estimated $124K sold.

Brevan Howard Capital Management first reported a position in CRBU in Q1 2024 and held it in 4 quarters. The position peaked at $196K in Q2 2025. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Caribou Biosciences position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 65,062 Caribou Biosciences shares in Q2 2026, an estimated $124K.
  • Brevan Howard Capital Management first reported a position in Caribou Biosciences in Q1 2024 and held it in 4 quarters.
  • Brevan Howard Capital Management's Caribou Biosciences position peaked at $196K in Q2 2025.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.